Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine TumorsJonathan Strosberg, Eric P. Krenning, Timothy J. Hobday et al.|New England Journal of Medicine|2017Cited by 3.2k
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell CarcinomaJonathan D. Schoenfeld, Robert I. Haddad, Glenn J. Hanna et al.|JAMA Oncology|2020Cited by 350
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)Devaki Shilpa Surasi, Morand Piert, Matthias Eiber et al.|European Urology|2023Cited by 90
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphomaReid W. Merryman, Eric D. Jacobsen, Natasha Edwin et al.|Blood Advances|2020Cited by 58
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantationReid W. Merryman, Philippe Armand, Robert Redd et al.|Blood Advances|2022Cited by 19